Skin Cancer

Nivolumab Monotherapy Provides Long Term Benefit Advanced Melanoma

Nivolumab Monotherapy Provides Long Term Benefit Advanced Melanoma

By

Dacarbazine, although once a staple of melanoma therapy, essentially has no current role in the treatment of any type or stage of melanoma.

Gender-Based Differences in Chemotherapy: Efficacy and Safety

Gender-Based Differences in Chemotherapy: Efficacy and Safety

By

Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.

BRAF Splice Variants May Mediate Resistance to RAF Inhibitors in Patients with Melanoma

BRAF Splice Variants May Mediate Resistance to RAF Inhibitors in Patients with Melanoma

By

The discovery could provide opportunities to target resistance driven by aberrantly spliced forms of BRAF V600E.

Moving Targets: Off-Label Prescribing of Targeted Therapies

Moving Targets: Off-Label Prescribing of Targeted Therapies

By

By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.

Encorafenib Plus Binimetinib Offers a New Option for MEK+BRAF Inhibition

Encorafenib Plus Binimetinib Offers a New Option for MEK+BRAF Inhibition

By

In the immunotherapy era, the optimal setting and sequencing of BRAF+MEK inhibition remains unresolved.

The Patient Behind the EHR: Oncologists Only See Half the Picture

The Patient Behind the EHR: Oncologists Only See Half the Picture

By

Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

By

Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

By

Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.

Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma

Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma

By

Pembrolizumab plus dabrafenib and trametinib showed a nonsignificant improvement in PFS, but also higher rates of grade 3 to grade 5 TRAEs in advanced melanoma.

First-Line Nivolumab Alone or With Ipilimumab Continues to Show Durable Survival Benefits in Advanced Melanoma

First-Line Nivolumab Alone or With Ipilimumab Continues to Show Durable Survival Benefits in Advanced Melanoma

By

First-line nivolumab with or without ipilimumab continues to show durable survival benefits in advanced, unresectable melanoma.

Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma

Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma

By

T-VEC elicited substantially higher ORR in a real-world population compared with the rate that was seen in the drug maker's phase 3 trial.

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

By

A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.

Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC

Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC

By

Researchers investigated whether the rates of immune-related adverse events linked to treatment with nivolumab or pembrolizumab were similar across 2 different cancer types.

The Optimal Neoadjuvant Regimen of Checkpoint Inhibitors in High-Risk Melanoma Is Unclear

The Optimal Neoadjuvant Regimen of Checkpoint Inhibitors in High-Risk Melanoma Is Unclear

By

Treatment with ipilimumab plus nivolumab in the neoadjuvant setting resulted in high patient response rates — but it was linked to high toxicity, as well.

Neoadjuvant Combination Checkpoint Inhibition May Be Feasible for Stage III Melanoma

Neoadjuvant Combination Checkpoint Inhibition May Be Feasible for Stage III Melanoma

By

Future studies on checkpoint inhibition in melanoma must evaluate ways of reducing toxicity.

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

By

In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.

Fall of Star Cancer Researcher Brings Broader Picture Into View

Fall of Star Cancer Researcher Brings Broader Picture Into View

By

Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.

Combination Immunotherapy Shown To Be Clinically Meaningful in Melanoma Metastatic to the Brain

Combination Immunotherapy Shown To Be Clinically Meaningful in Melanoma Metastatic to the Brain

By

Updated results show prolonged responses to brain metastases.

Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response

Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response

By

Existing studies that summarize the risks of breast implants are not adequately powered to detect all harms, alleged authors of a study including nearly 100,000 patient outcomes.

Predicting Response to Immunotherapy in Late-Stage Melanoma

Predicting Response to Immunotherapy in Late-Stage Melanoma

By

A new model has the potential to identify patients with melanoma who could benefit from treatment with checkpoint inhibitors.

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

By

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

By

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

Exploring the Role of Immunotherapy in Melanoma Brain Metastases

Exploring the Role of Immunotherapy in Melanoma Brain Metastases

By

Although checkpoint inhibitors are active against melanoma-linked brain metastases, researchers are interested in exploring combination approaches.

Predictors of Response to Checkpoint Inhibitors in Melanoma Revealed

Predictors of Response to Checkpoint Inhibitors in Melanoma Revealed

By

A computational tool appears to accurately tease out the portion of patients who might respond to checkpoint inhibitors from those who are likely to be resistant.

Limited Local Lymph Node Excision Plus Radiotherapy May Be Effective in Melanoma

Limited Local Lymph Node Excision Plus Radiotherapy May Be Effective in Melanoma

By

Previous studies have evaluated the effects of limited local node excision plus radiotherapy among patients with melanoma in this subgroup, but had conflicting results.

Bispecific Antibodies in Cancer

Bispecific Antibodies in Cancer

By

Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.

Adjuvant Bevacizumab May Not Improve Overall Survival in Resected Melanoma

Adjuvant Bevacizumab May Not Improve Overall Survival in Resected Melanoma

By

Previous studies have demonstrated that the vascular endothelial growth factor inhibitor bevacizumab is active in melanoma, and may be effective in the maintenance setting.

Tapping Social Media for Skin Cancer Prevention: What You Can Do

Tapping Social Media for Skin Cancer Prevention: What You Can Do

Any images and personal stories that remind people about skin cancer, what to look for, even scars after surgery, really help save lives.

Frequency of Tanning, Risk for Melanoma Higher in Gym Tanners

Frequency of Tanning, Risk for Melanoma Higher in Gym Tanners

By

The use of tanning beds and/or booths and their availability in gyms may increase the frequency of indoor tanning for physically active adults, a combination that further exacerbates their risk for melanoma.

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

By

Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs